Compare
Incannex Healthcare Inc. vs Actinium Pharmaceuticals, Inc. vs Connect Biopharma Holdings Ltd vs Avalo Therapeutics, Inc.
| Latest fiscal year | Incannex Healthcare Inc. IXHL | Actinium Pharmaceuticals, Inc. ATNM | Connect Biopharma Holdings Ltd CNTB | Avalo Therapeutics, Inc. AVTX |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $86.0K | $90.0K | $64.0K | $59.0K |
| Revenue growth (YoY) | +616.7% | n/a | -99.8% | -86.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$46.88M | -$33.89M | -$55.48M | -$78.26M |
| EPS (Diluted) | -$1.35 | -$1.09 | -$1.00 | -$5.84 |
| Operating cash flow | -$12.51M | -$24.58M | -$51.21M | -$51.46M |
| Free cash flow | -$12.52M | -$24.68M | -$51.64M | n/a |
| Cash & equivalents | $15.04M | $48.00M | $38.34M | $15.86M |
| Total assets | $20.45M | $51.77M | $56.08M | $116.46M |
| Total liabilities | $7.06M | $43.94M | $14.10M | $33.41M |
| Shareholders' equity | $13.39M | $7.83M | $41.98M | $83.05M |
| Return on year-end equity | -350.2% | -432.6% | -132.2% | -94.2% |
| Shares outstanding | 194.38M | 31.20M | 56.44M | 18.51M |
Revenue, most recent five fiscal years
| Fiscal year | Incannex Healthcare Inc. | Actinium Pharmaceuticals, Inc. | Connect Biopharma Holdings Ltd | Avalo Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $86.0K Ended 2025-06-30 | $90.0K Ended 2025-12-31 | $64.0K Ended 2025-12-31 | $59.0K Ended 2025-12-31 |
| 1 year earlier | $12.0K Ended 2024-06-30 | n/a | $26.03M Ended 2024-12-31 | $441.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $81.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $1.92M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.03M Ended 2022-12-31 | n/a | $18.05M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.14M Ended 2021-12-31 | n/a | $5.40M Ended 2021-12-31 |